These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 32663537)

  • 1. Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients.
    Levin-Epstein R; Cook RR; Wong JK; Stock RG; Jeffrey Demanes D; Collins SP; Aghdam N; Suy S; Mantz C; Katz AJ; Nickols NG; Miszczyk L; Napieralska A; Namysl-Kaletka A; Prionas ND; Bagshaw H; Buyyounouski MK; Cao M; Mahal BA; Shabsovich D; Dang A; Yuan Y; Rettig MB; Chang AJ; Jackson WC; Spratt DE; Lehrer EJ; Zaorsky NG; Kupelian PA; Steinberg ML; Horwitz EM; Jiang NY; Kishan AU
    Radiother Oncol; 2020 Oct; 151():26-32. PubMed ID: 32663537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SBRT and HDR brachytherapy produce lower PSA nadirs and different PSA decay patterns than conventionally fractionated IMRT in patients with low- or intermediate-risk prostate cancer.
    Kishan AU; Wang PC; Upadhyaya SK; Hauswald H; Demanes DJ; Nickols NG; Kamrava M; Sadeghi A; Kupelian PA; Steinberg ML; Prionas ND; Buyyounouski MK; King CR
    Pract Radiat Oncol; 2016; 6(4):268-275. PubMed ID: 26850649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-Institutional Analysis of Prostate-Specific Antigen Kinetics After Stereotactic Body Radiation Therapy.
    Jiang NY; Dang AT; Yuan Y; Chu FI; Shabsovich D; King CR; Collins SP; Aghdam N; Suy S; Mantz CA; Miszczyk L; Napieralska A; Namysl-Kaletka A; Bagshaw H; Prionas N; Buyyounouski MK; Jackson WC; Spratt DE; Nickols NG; Steinberg ML; Kupelian PA; Kishan AU
    Int J Radiat Oncol Biol Phys; 2019 Nov; 105(3):628-636. PubMed ID: 31276777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-response with stereotactic body radiotherapy for prostate cancer: A multi-institutional analysis of prostate-specific antigen kinetics and biochemical control.
    Levin-Epstein RG; Jiang NY; Wang X; Upadhyaya SK; Collins SP; Suy S; Aghdam N; Mantz C; Katz AJ; Miszczyk L; Napieralska A; Namysl-Kaletka A; Prionas N; Bagshaw H; Buyyounouski MK; Cao M; Agazaryan N; Dang A; Yuan Y; Kupelian PA; Zaorsky NG; Spratt DE; Mohamad O; Feng FY; Mahal BA; Boutros PC; Kishan AU; Juarez J; Shabsovich D; Jiang T; Kahlon S; Patel A; Patel J; Nickols NG; Steinberg ML; Fuller DB; Kishan AU
    Radiother Oncol; 2021 Jan; 154():207-213. PubMed ID: 33035622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Refining the definition of biochemical failure in the era of stereotactic body radiation therapy for prostate cancer: The Phoenix definition and beyond.
    Ma TM; Roy S; Wu X; Mantz C; Fuller D; Miszczyk L; Napieralska A; Namysł-Kaletka A; Bagshaw HP; Buyyounouski MK; Glicksman R; Loblaw DA; Katz A; Upadhyaya SK; Nickols N; Steinberg ML; Philipson R; Aghdam N; Suy S; Pepin A; Collins SP; Boutros P; Rettig MB; Calais J; Wang M; Zaorsky N; Kishan AU
    Radiother Oncol; 2022 Jan; 166():1-7. PubMed ID: 34774650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early Prostate-Specific Antigen Kinetics for Low- and Intermediate-Risk Prostate Cancer Treated With Definitive Radiation Therapy.
    Pirlamarla AK; Hansen CC; Deng M; Handorf E; Paly J; Wong JK; Hallman MA; Chen DYT; Geynisman DM; Kutikov A; Horwitz EM
    Pract Radiat Oncol; 2022; 12(1):60-67. PubMed ID: 34303033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brachytherapy boost (BT-boost) or stereotactic body radiation therapy boost (SBRT-boost) for high-risk prostate cancer (HR-PCa).
    Peyraga G; Lizee T; Khalifa J; Blais E; Mauriange-Turpin G; Supiot S; Krhili S; Tremolieres P; Graff-Cailleaud P
    Cancer Radiother; 2021 Jun; 25(4):400-409. PubMed ID: 33478838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvage brachytherapy for locally-recurrent prostate cancer after radiation therapy: A comparison of efficacy and toxicity outcomes with high-dose rate and low-dose rate brachytherapy.
    Henríquez López I; González-San Segundo C; Vegas JO; Gutierrez C; Hervas A; Cabeza Rodriguez MÁ; Valero Albarrán J; Rodríguez Villalba S; Álvarez Gonzalez A; Sancho Pardo G; Zapatero A; Álvaro PC
    Radiother Oncol; 2019 Dec; 141():156-163. PubMed ID: 31570236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response.
    Jabbari S; Weinberg VK; Kaprealian T; Hsu IC; Ma L; Chuang C; Descovich M; Shiao S; Shinohara K; Roach M; Gottschalk AR
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):228-34. PubMed ID: 21183287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does prostate-specific antigen nadir predict longer-term outcomes of prostate cancer after neoadjuvant and adjuvant androgen deprivation therapy in conjunction with brachytherapy?
    Morris LM; Izard MA; Wan WY
    Brachytherapy; 2015; 14(3):322-8. PubMed ID: 25487524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis.
    Smith GD; Pickles T; Crook J; Martin AG; Vigneault E; Cury FL; Morris J; Catton C; Lukka H; Warner A; Yang Y; Rodrigues G
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):505-16. PubMed ID: 25596107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early outcomes of high-dose-rate brachytherapy combined with ultra-hypofractionated radiation in higher-risk prostate cancer.
    Gorovets D; Hopkins M; Kollmeier M; Moore A; Goel A; Shasha D; Brennan V; McBride S; Cohen G; Damato AL; Zelefsky MJ
    Brachytherapy; 2021; 20(6):1099-1106. PubMed ID: 34588146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radical dose escalation by high-dose-rate brachytherapy for localized prostate cancer-Significance of prostate-specific antigen nadir level within 18 months as correlation for long-term biochemical control.
    Schroeder C; Geiger F; Siebert FA; Baumann R; Bockelmann G; Schultze J; Kimmig B; Dunst J; Galalae R
    Brachytherapy; 2019; 18(1):8-12. PubMed ID: 30482622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.
    Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-reported outcomes after Low-dose-rate versus High-dose-rate brachytherapy boost in combination with external beam radiation for intermediate and high risk prostate cancer.
    Dhere VR; Fischer-Valuck BW; Goyal S; Liu Y; Morgan TM; Ghavidel E; Moghanaki DM; Hershatter BW; Patel PR; Jani AB; Godette KD; Rossi PJ; Patel SA
    Brachytherapy; 2021; 20(6):1130-1138. PubMed ID: 34417136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereotactic Body Radiation Therapy and High-Dose-Rate Brachytherapy Boost in Combination With Intensity Modulated Radiation Therapy for Localized Prostate Cancer: A Single-Institution Propensity Score Matched Analysis.
    Chen WC; Li Y; Lazar A; Altun A; Descovich M; Nano T; Ziemer B; Sudhyadhom A; Cunha A; Thomas H; Gottschalk A; Hsu IC; Roach M
    Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):429-437. PubMed ID: 33385496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time to PSA rise differentiates the PSA bounce after HDR and LDR brachytherapy of prostate cancer.
    Burchardt W; Skowronek J
    J Contemp Brachytherapy; 2018 Feb; 10(1):1-9. PubMed ID: 29619050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical Control and Toxicity Outcomes of Stereotactic Body Radiation Therapy Versus Low-Dose-Rate Brachytherapy in the Treatment of Low- and Intermediate-Risk Prostate Cancer.
    Gogineni E; Rana Z; Soberman D; Sidiqi B; D'Andrea V; Lee L; Potters L; Parashar B
    Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1232-1242. PubMed ID: 33171199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose-rate brachytherapy with external beam radiotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer.
    Yamazaki H; Masui K; Suzuki G; Aibe N; Shimizu D; Kimoto T; Yamada K; Ueno A; Matsugasumi T; Yamada Y; Shiraishi T; Fujihara A; Okihara K; Yoshida K; Nakamura S
    Sci Rep; 2021 Mar; 11(1):6165. PubMed ID: 33731856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Randomized Trial Comparing Quality of Life After Low-Dose Rate or High-Dose Rate Prostate Brachytherapy Boost With Pelvic External Beam Radiation Therapy.
    Crook J; Moideen N; Arbour G; Castro F; Araujo C; Batchelar D; Halperin R; Hilts M; Kim D; Petrik D; Rose J; Cheng JC; Bachand F
    Int J Radiat Oncol Biol Phys; 2024 Sep; 120(1):59-68. PubMed ID: 38493901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.